(Q33863531)

29 July 2017

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers (English)

1 reference

29 July 2017

1 reference

6

Judy E Garber

1 reference

29 July 2017

Larissa J Lee

1

1 reference

29 July 2017

Brian Alexander

2

1 reference

29 July 2017

Stuart J Schnitt

3

1 reference

29 July 2017

Amy Comander

4

1 reference

29 July 2017

Bridget Gallagher

5

1 reference

29 July 2017

Nadine Tung

7

1 reference

29 July 2017

language of work or name

English

0 references

publication date

24 January 2011

1 reference

29 July 2017

1 reference

29 July 2017

117

1 reference

29 July 2017

14

1 reference

29 July 2017

3093-3100

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Metastatic behavior of breast cancer subtypes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Triple-negative breast cancer: risk factors to potential targets

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Triple-negative breast cancer: clinical features and patterns of recurrence

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Prognostic markers in triple-negative breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

BRCA1 dysfunction in sporadic basal-like breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Basal-like breast cancer and the BRCA1 phenotype

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Survival and prognostic factors in BRCA1-associated breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Hallmarks of 'BRCAness' in sporadic cancers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Repeated observation of breast tumor subtypes in independent gene expression data sets

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Molecular portraits of human breast tumours

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

5 July 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25911

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25911

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25911

Survival and recurrence after breast cancer in BRCA1/2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25911

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25911

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25911

BRCA-associated breast cancer in young women

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086795

Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21264845

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21264845

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Familial invasive breast cancers: worse outcome related to BRCA1 mutations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21264845

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.25911

1 reference

29 July 2017

1 reference

29 July 2017

1 reference